Physicians highlight need for improved non-opioid treatments for opioid use disorder
Opioids are synthetic or natural agents that stimulate opioid receptors in the brain and nervous system and are often used to…
Central Nervous System
-
-
MHLW approves Eli Lilly’s Kinsula to treat Alzheimer’s in Japan
Eli Lilly has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kisunla (donanemab-azbt) to…
-
Teva touts safety profile of once monthly schizophrenia therapy
Teva Pharmaceuticals has shared new safety data from the Phase III SOLARIS trial and a Phase I study of extended-release…
-
FDA approves Zevra Therapeutics’ Miplyffa for Niemann-Pick disease
Zevra Therapeutics has announced US Food and Drug Administration (FDA) approval for Miplyffa (arimoclomol) to treat Niemann-Pick disease type C…
-
Sanofi eyes approval after MS therapy slows disease progression by 31%
Sanofi is eyeing global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing secondary progressive multiple sclerosis…
-
Orbis and Vivtex partner to develop oral macrocycle drugs
Orbis Medicines has announced a research collaboration and an option to an exclusive licence to Vivtex to support the development…
-
Nura Bio secures funding to advance neuroprotective therapies
Nura Bio has secured an additional $68m in a Series A financing round to advance the development of its neuroprotective…
-
Prodrugs and patents: Enhancing therapy adherence and reducing side effects
As the approval date for Bristol Myers Squibb’s (BMS) schizophrenia drug KarXT (xanomeline-trospium) fast approaches, the schizophrenia field eagerly anticipates…
-
Athira’s stock topples after Alzheimer’s drug flops in Phase II/III trial
Athira Pharma has released topline data from the Phase II/III LIFT-AD trial of its lead Alzheimer’s disease therapy, fosgonimeton. The…
-
Actimed’s ALS candidate wins FDA orphan drug designation
The US Food and Drug Administration (FDA) has granted an orphan drug designation to Actimed Therapeutics’ S-oxprenolol (ACM-002) for the…
